Back to Search
MICHAEL PINS, M.D.
M.D.
Specialist
NPI: 1639155328IndividualAccepts Medicare
Specialties, Licenses & Credentials
SpecialistPrimary
Specialist
Code: 174400000X
036093124(IL)
CMS Specialties
PrimaryPATHOLOGY
Education
RUSH MEDICAL COLLEGE OF RUSH UNIVERSITY
Class of 1989
Research & Publications (20)
Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report.
PMID 15343364·Prostate Cancer Prostatic Dis·2004
8-other
Solitary fibrous tumor of the prostate a report of 2 cases and review of the literature.
PMID 11175651·Arch Pathol Lab Med·2001
5-case
Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.
PMID 19634157·Cancer·2009
3-trial
Suppressive roles of calreticulin in prostate cancer growth and metastasis.
PMID 19608864·Am J Pathol·2009
7-preclinical
Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
PMID 19447876·Clin Cancer Res·2009
8-other
A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.
PMID 18829509·Clin Cancer Res·2008
3-trial
U19/Eaf2 knockout causes lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma and prostatic intraepithelial neoplasia.
PMID 17873910·Oncogene·2008
7-preclinical
Recommendations for collection and handling of specimens from group breast cancer clinical trials.
PMID 18955459·J Clin Oncol·2008
8-other
Tissue-based research in kidney cancer: current challenges and future directions.
PMID 18559586·Clin Cancer Res·2008
6-review
The methodology used to measure differential gene expression affects the outcome.
PMID 18166675·J Biomol Tech·2007
4-observational
Expression and function of the human androgen-responsive gene ADI1 in prostate cancer.
PMID 17786183·Neoplasia·2007
4-observational
Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
PMID 17085199·J Urol·2006
8-other
Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story.
PMID 17409827·J Thorac Oncol·2006
8-other
Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle.
PMID 16891459·Mol Cancer Ther·2006
7-preclinical
Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer.
PMID 16545117·BMC Cancer·2006
4-observational
Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.
PMID 16615097·Cancer·2006
3-trial
A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.
PMID 16760642·Cancer Biol Ther·2006
3-trial
Characterization of a method for profiling gene expression in cells recovered from intact human prostate tissue using RNA linear amplification.
PMID 16786039·Prostate Cancer Prostatic Dis·2006
4-observational
The leader sequence triggers and enhances several functions of clusterin and is instrumental in the progression of human prostate cancer in vivo and in vitro.
PMID 16879694·BJU Int·2006
8-other
Tumor necrosis factor promotes differential trafficking of bladder mast cells in neurogenic cystitis.
PMID 16407045·J Urol·2006
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1775 W DEMPSTER ST
PARK RIDGE, IL 60068 - Phone
- (847) 723-8957
Quick Facts
- NPI
- 1639155328
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 37
- Publications
- 20
Are you this provider?
Claim Your Profile